DISTRICT OF COLUMBIA MUNICIPAL REGULATIONS for PHARMACISTS

CHAPTER 65 PHARMACISTS

Secs.

6500 GENERAL PROVISIONS

6500.1 This chapter shall apply to applicants for and holders of a license to practice pharmacy and to pharmacy interns.

6500.2 Chapters 40 (Health Occupations: General Rules), and 41 (Health Occupations: Administrative Procedures) of this title shall supplement this chapter.

6501 TERM OF LICENSE

6501.1 Subject to § 6501.2, a license issued pursuant to this chapter shall expire at 12:00 midnight of the last day of February of each odd-numbered year.

6501.2 If the Director changes the renewal system pursuant to § 4006.3 of Chapter 40 of this title, a license issued pursuant to this chapter expires at 12:00 midnight of the last day of the month of the birthdate of the holder of the license, or other date established by the Director.

6502 EDUCATION AND TRAINING REQUIREMENTS

6502.1 Except as otherwise provided in this chapter an applicant shall furnish proof satisfactory to the Board, that the applicant:

(a) Has successfully completed an educational program in the practice of pharmacy and holds a Bachelor of Science in Pharmacy or Doctor of Pharmacy degree from a school of pharmacy:

(1) Accredited by the American Council on Pharmaceutical Education (ACPE) at the time the applicant graduates; and

(2) With at least a five (5) year curriculum at the time of graduation, unless the applicant graduated prior to January 1, 2003, in which case a four (4) year curriculum will be accepted; and

(b) Has successfully completed the introductory and advanced pharmacy experience hourly requirements in accordance with ACPE standards.

6503 APPLICANTS EDUCATED IN FOREIGN COUNTRIES

6503.1 The Board may grant a license to practice pharmacy to an applicant who completed an educational program in a foreign country, which program was not recognized by the ACPE, if the applicant:

(a) Meets all requirements of this chapter except for § 6502.1(a);

(b) Demonstrates to the satisfaction of the Board that the applicant's education and training are substantially equivalent to the requirements of this chapter and the Act by submitting the documentation required by this section;

(c) Has completed a minimum of one thousand five hundred (1,500) hours of independent pre-licensure professional practice that provides experience in community, institutional, and clinical pharmacy practices under the supervision of a licensed pharmacist in the United States who is registered with the Board as the applicant's preceptor;

(d) Furnishes proof satisfactory to the Board that the applicant holds a pharmacy degree from a school of pharmacy with at least a five (5) year curriculum at the time of graduation, unless the applicant graduated prior to January 1, 2003, in which case a four (4) year curriculum will be accepted;

(e) Possesses a Foreign Pharmacy Graduate Examination Committee (FPGEC) Certification; and

(f) Received passing scores on the North American Pharmacist Licensure Examination (NAPLEX) or its successor, and the Multistate Pharmacy Jurisprudence Examination for the District of Columbia (MPJE) or its

successor. The passing score of the NAPLEX and MPJE are the passing scores established by the National Association of Boards of Pharmacy on each test that forms a part of the examinations.

6503.2 The independent pre-licensure professional practice required under § 6503.1(c) shall be completed within one (1) year after licensure as a pharmacy intern in the District of Columbia. However, the Board may grant up to a six (6)-month extension of this period for good cause shown.

6503.3 Credit for pre-licensure professional practice performed in the District of Columbia shall:

(a) Not begin to accrue until the Board has registered the intern in accordance with the procedures set forth in § 6509 of this chapter;

(b) Only be given for pre-licensure professional practice hours performed as part of a formalized internship program and under the supervision of the individual's assigned preceptor; and

(c) Not be given for more than forty-five (45) hours of pre-licensure professional practice hours per week.

6503.4 An applicant under this section shall submit with their completed application certified transcripts of the applicant's pharmacy educational record(s). However, the Board may waive this requirement on a showing of extraordinary hardship if the applicant is able to establish by substitute documentation that the applicant possesses the requisite education and degrees.

6503.5 If a document required by this chapter is in a language other than English, the applicant shall arrange for its translation into English by a translation service acceptable to the Board and shall submit to the Board a translation signed by the translator attesting to its accuracy.

6503.6 The Board may interview an applicant under this section to determine whether the applicant's education or training meets the requirements of the Act and this chapter.

6504 LICENSE BY EXAMINATION

6504.1 To qualify for a license by examination, an applicant shall:

(a) Meet the education requirements set forth under § 6502.1(a), or if the applicant was educated in a foreign country meet the requirements set forth under § 6503;

(b) Meet the training requirements set forth in § 6502 or § 6503;

(c) Receive a passing score on each test that forms a part of the NAPLEX, or its successor, which shall be the passing score as determined by the NABP;

(d) Receive a passing score on each test that forms a part of the MPJE for the District of Columbia, or its successor, which shall be the passing score as determined by the NABP;

(e) Be at least 18 years of age; and

(f) Have not been convicted of a crime involving moral turpitude or bearing directly on the fitness of the applicant to be licensed.

6504.2 An applicant for licensure by examination, who has previously successfully completed the NAPLEX and/or MPJE examinations, but has not actively engaged in the practice of pharmacy in the United States or was not actively licensed as a pharmacist in the United States for more than five (5) years prior to the date of the application, in addition to the other requirements of this section, shall be required to do the following in order to qualify for licensure under this section:

(a) Retake the NAPLEX and MPJE examinations; and

(b) Register as a Pharmacy Intern and complete an additional pharmacy internship consisting of seven hundred and fifty (750) hours of independent pre-licensure professional practice under the supervision of a licensed pharmacist who uses the standards for pre-licensure professional practice described in § 6502 of this chapter.

6504.3 To apply for a license by examination, an applicant shall:

(a) Submit a completed application to the Board on the required forms and include:

(1) The applicant's social security number on the application. If the applicant does not have a social security number, the applicant shall submit with the application a sworn affidavit, under penalty of perjury, stating that he or she does not have a social security number; and

(2) Two (2) recent passport-type photographs of the applicant's face measuring two inches by two inches (2" x 2"), which clearly expose the area from the top of the forehead to the bottom of the chin; and

(3) One (1) clear photocopy of a U.S. government-issued photo ID, such as a driver's license, as proof of identity.

(b) Submit official transcripts directly to the Board of Pharmacy from each educational institution in a manner, as directed on the application form, that ensures the authenticity of the transcripts, which shall verify that the applicant has successfully completed an educational program in the practice of pharmacy meeting the requirements set forth in § 6502.1(a) of this chapter;

(c) Applicants educated in foreign countries must submit a Foreign Pharmacy Graduate Examination Committee (FPGEC) Certification in lieu of an official transcript;

(d) Submit proof acceptable to the Board that the applicant has successfully completed a pharmacy internship meeting the training requirements set forth in § 6502 or § 6503 of this chapter;

(e) Pay all required fees; and

(f) Successfully complete the NAPLEX and MPJE examinations after receiving Board approval to take the examinations and arrange to have the score results sent directly to the Board.

6504.4 An applicant under this section shall successfully complete the NAPLEX and MPJE examinations within one (1) year from the date the Board approves the applicant to take the examinations.

6504.5 If an applicant under this section fails to successfully complete the NAPLEX and MPJE examinations within one (1) year from the date of approval to take the exam, his or her application shall be considered abandoned and closed by the Board. The applicant shall thereafter be required to reapply, comply with the current requirements for licensure, and pay the required fees.

6504.6 If an applicant under this section fails to successfully complete the NAPLEX and MPJE examinations within one (1) year from the date of approval to take the exam, then upon expiration of his or her supervised practice letter, the applicant shall immediately cease from practicing. Thereafter the applicant may perform only the duties of a pharmacy technician until the applicant receives a pharmacist license.

6504.7 A supervised practice letter issued under this section is not renewable and shall expire one (1) year from the date of issuance.

6505 LICENSE BY SCORE TRANSFER

6505.1 To qualify for a license by score transfer, an applicant shall:

(a) Meet the education requirements set forth under § 6502.1(a), or if the applicant was educated in a foreign country meet the requirements set forth

under § 6503;

(b) Meet the training requirements set forth in § 6502 or § 6503;

(c) Have received a passing score on each test that forms a part of the NAPLEX, or its successor, which shall be the passing score as determined by the NABP;

(d) Receive a passing score on each test that forms a part of the MPJE for the District of Columbia, or its successor, which shall be the passing score as determined by the NABP;

(e) Be at least 18 years of age;

(f) Have not been convicted of a crime involving moral turpitude or bearing directly on the fitness of the applicant to be licensed; and

(g) Have requested a score transfer to the District of Columbia at the time the applicant applied to take his or her initial NAPLEX examination.

6505.2 To apply for a license by score transfer, an applicant shall:

(a) Submit a completed application to the Board on the required forms and include:

(1) The applicant's social security number on the application. If the applicant does not have a social security number, the applicant shall submit with the application a sworn affidavit, under penalty of perjury, stating that he or she does not have a social security number;

(2) Two (2) recent passport-type photographs of the applicant's face measuring two inches by two inches (2" x 2"), which clearly expose the area from the top of the forehead to the bottom of the chin; and

(3) One (1) clear photocopy of a U.S. government-issued photo ID, such as a driver's license, as proof of identity.

(b) Submit the NABP score transfer form with the application for licensure;

(c) Submit proof acceptable to the Board that the applicant has successfully completed a pharmacy internship meeting the training requirements set forth in § 6502 or § 6503 of this chapter;

(d) Pay all required fees; and

(e) Successfully complete the MPJE examination after receiving Board approval to take the examination and arrange to have the score result sent directly to the

Board.

6505.3 An applicant under this section shall successfully complete the MPJE examination within one (1) year from the date the Board approves the applicant to take the examination.

6505.4 If an applicant under this section fails to successfully complete the MPJE examination within one (1) year from the date of approval to take the exam, his or her application shall be considered abandoned and closed by the Board. The applicant shall thereafter be required to reapply, comply with the current requirements for licensure, and pay the required fees.

6505.5 If an applicant under this section fails to successfully complete the MPJE examination within one (1) year from the date of approval to take the exam, then upon expiration of his or her supervised practice letter, the applicant shall immediately cease from practicing. Thereafter the applicant may become registered as a registered pharmacy technician, if he or she meets the requirements for registration, and perform only the duties of a registered pharmacy technician until the applicant receives a pharmacist license.

6505.6 A supervised practice letter issued under this section is not renewable and shall expire one (1) year from the date of issuance.

6506 LICENSE BY RECIPROCITY WITH LICENSURE TRANSFER

6506.1 To qualify for a license by reciprocity with license transfer, an applicant shall:

(a) Meet the education requirements set forth under § 6502.1(a), or if the applicant was educated in a foreign country meet the requirements set forth under § 6503;

(b) Have met the training requirements in the state in which his or her initial license was obtained;

(c) Have received a passing score on each test that forms a part of the NAPLEX, or its successor, which shall be the passing score as determined by the NABP;

(d) Receive a passing score on each test that forms a part of the MPJE for the District of Columbia, or its successor, which shall be the passing score as determined by the NABP;

(e) Be at least 18 years of age;

(f) Have not been convicted of a crime involving moral turpitude or bearing directly on the fitness of the applicant to be licensed; and

(g) Obtain a NABP licensure transfer to the District of Columbia.

6506.2 To apply for a license by reciprocity with licensure transfer, an applicant shall:

(a) Submit a completed application to the Board on the required forms and include:

(1) The applicant's social security number on the application. If the applicant does not have a social security number, the applicant shall submit with the application a sworn affidavit, under penalty of perjury, stating that he or she does not have a social security number;

(2) Two (2) recent passport-type photographs of the applicant's face measuring two inches by two inches (2" x 2"), which clearly expose the area from the top of the forehead to the bottom of the chin; and

(3) One (1) clear photocopy of a U.S. government-issued photo ID, such as a driver's license, as proof of identity.

(b) Submit the NABP licensure transfer form to the District of Columbia with the application for licensure;

(c) Pay all required fees; and

(d) Successfully complete the MPJE examination after receiving Board approval to take the examination and arrange to have the score result sent directly to the Board.

6506.3 An applicant under this section shall successfully complete the MPJE examination within six (6) months from the date the Board approves the applicant to take the examination.

6506.4 If an applicant under this section fails to successfully complete the MPJE examination within six (6) months from the date of approval to take the exam, his or her application shall be considered abandoned and closed by the Board. The applicant shall thereafter be required to reapply, comply with the current requirements for licensure, and pay the required fees.

6506.5 If an applicant under this section fails to successfully complete the MPJE examination within six (6) months from the date of approval to take the exam, then upon expiration of his or her supervised practice letter, the applicant shall immediately cease from practicing. Thereafter the applicant may become registered as a registered pharmacy technician, if he or she meets the requirements for registration, and perform only the duties of a registered pharmacy technician until the applicant receives a pharmacist license.

6506.6 A supervised practice letter issued under this section is not renewable and shall expire six (6) months from the date of issuance.

6507 LICENSE BY RECIPROCITY WITH WAIVER OF LICENSURE TRANSFER FORM

6507.1 Only applicants who were previously licensed in the District of Columbia to practice pharmacy may apply for licensure by reciprocity with waiver of licensure transfer.

6507.2 To apply for a license by reciprocity with waiver of licensure transfer form, an applicant shall:

(a) Submit a completed application to the Board on the required forms and include:

(1) The applicant's social security number on the application. If the applicant does not have a social security number, the applicant shall submit with the application a sworn affidavit, under penalty of perjury, stating that he or she does not have a social security number;

(2) Two (2) recent passport-type photographs of the applicant's face measuring two inches by two inches (2" x 2"), which clearly expose the area from the top of the forehead to the bottom of the chin; and

(3) One (1) clear photocopy of a U.S. government-issued photo ID, such as a driver's license, as proof of identity.

(b) Submit proof acceptable to the Board of previous licensure in the District of Columbia to practice pharmacy;

(c) Submit verification of current licensure in good standing in another state to practice pharmacy; and

(d) Pay all required fees.

6508 SUPERVISED PRACTICE OF PHARMACY

6508.1 Only the following persons may practice pharmacy under supervision:

(a) An applicant for a pharmacist license whose initial application for licensure is pending before the Board and who has received a supervised practice letter from the Board, but shall be limited to the same scope of duties as a registered pharmacy intern;

(b) A licensee who is working under supervised practice pursuant to an Order of the Board;

(c) A pharmacy intern who is registered with the Board, subject to the limitations set forth under District of Columbia law and regulations; or

(d) An applicant who is required pursuant to this chapter to complete professional practice hours in order to obtain licensure, reinstatement of licensure, or reactivation of licensure.

6508.2 A supervisor shall be responsible for ensuring that the individual(s) under his or her supervision is authorized to practice under supervision and may be subject to disciplinary action for supervising unlicensed or unauthorized personnel.

6508.3 For purposes of this section, supervision shall mean that the supervisor is physically present in the pharmacy area and shall include personal observation where appropriate, evaluation, oversight, review, and correction of services provided by the supervisee.

6508.4 A supervisor shall be fully responsible for supervised practice by a supervisee during the period of supervision, and is subject to disciplinary action for any violation of the Act or this chapter by the person being supervised.

6508.5 A supervisee shall be subject to all applicable provisions of the Act and this chapter.

6508.6 If the Board finds that a person practicing under supervision has violated the Act or this title, the Board may, in addition to any other disciplinary actions permitted by the Act, deny, revoke, suspend, or restrict the privilege of the supervisee to practice.

6509 REGISTRATION OF PHARMACY INTERNS

6509.1 Except as provided in 6509.2 of this chapter, this section shall apply to pharmacy interns who are performing independent, pre-licensure professional practice in satisfaction of the internship required by § 6502 or § 6503 under the supervision of a pharmacist licensed in the District of Columbia.

6509.2 REPEALED

6509.3 A pharmacy intern is required to be registered with the Board as an intern before being employed as an intern in a pharmacy in the District or beginning an internship.

6509.4 Credit for internship hours performed in the District of Columbia shall not begin to accrue until the Board has registered the intern and shall only be given for pre-licensure professional practice hours performed as part of a formalized internship program and under the supervision of the individual's assigned preceptor.

6509.5 To qualify to register to perform a pharmacy internship, an applicant shall:

(a) Meet the education requirements set forth in § 6502 or § 6503, or be currently enrolled in an educational program in the practice of pharmacy at an ACPE-accredited school or a school pending initial ACPE accreditation;

(b) Be at least 18 years of age; and

(c) Have not been convicted of a crime involving moral turpitude or bearing directly on the fitness of the applicant to be registered.

6509.6 To register as a pharmacy intern, an applicant shall:

(a) Submit a completed application to the Board on the required forms and include:

(1) The applicant's social security number on the application. If the applicant does not have a social security number, the applicant shall submit with the application a sworn affidavit, under penalty of perjury, stating that he or she does not have a social security number;

(2) Two (2) recent passport-type photographs of the applicant's face measuring two inches by two inches (2" x 2"), which clearly expose the area from the top of the forehead to the bottom of the chin; and

(3) One (1) clear photocopy of a U.S. government-issued photo ID, such as a driver's license, as proof of identity.

(b) Submit official transcripts directly to the Board of Pharmacy from each educational institution in a manner, as directed on the application form, that ensures the authenticity of the transcripts, which shall verify that the applicant has successfully completed an educational program in the practice of pharmacy meeting the requirements set forth in § 6502 or § 6503 of this chapter or is currently enrolled in an educational program in the practice of pharmacy at an ACPE accredited school;

(c) Applicants educated in foreign countries must submit a Foreign Pharmacy Graduate Examination Committee (FPGEC) Certification in lieu of an official transcript;

(d) Pay all required fees; and

(e) If the applicant is a foreign-trained student applying under § 6503, submit a completed preceptor form signed by the applicant's preceptor which shall include:

(1) The name and District of Columbia pharmacist license number of the preceptor;

(2) The location where the internship will be performed;

(3) A description of the duties the intern will perform;

(4) The expected start date of the internship; and

(5) The Oath of Preceptor set forth in § 6511.3 of this chapter.

6509.7 For foreign-trained applicants registering as an intern, a registration as a pharmacy intern shall expire one (1) year from the date of its issuance. The Board may, in its discretion, renew a registration for successive periods of one (1) year for good cause shown if the pharmacy intern demonstrates due diligence in working toward completing the clinical internship requirement of § 6503.

6509.8 For applicants enrolled in a college of pharmacy at the time of registering as an intern, a registration as a pharmacy intern shall be valid until whichever of the following occurs first:

(a) While he or she is enrolled in a pharmacy program and for not more than one year after his or her graduation from the pharmacy program;

(b) Until such intern is expelled, suspended, dismissed or withdraws from an approved pharmacy program; or

(c) Until such intern becomes licensed as a pharmacist.

6510 PRE-LICENSURE PROFESSIONAL PRACTICE OF PHARMACY INTERNS

6510.1 This section shall apply to pharmacy interns who are performing independent, pre-licensure professional practice in satisfaction of the internship required by § 6503 under the direct supervision of a pharmacist in the District, or who are otherwise registered with the Board to practice as a pharmacy intern.

6510.2 No person not properly registered with the Board as a pharmacy intern shall take, use, or exhibit the title of pharmacy intern, intern, extern, graduate pharmacist or any other similar title.

6510.3 A pharmacy intern may practice as an intern under the supervision of any pharmacist licensed in good standing in the District of Columbia. However, the Board shall only grant pre-licensure professional practice hours for those pharmacy tasks:

(a) Performed under the supervision of the intern's Board approved assigned preceptor; and

(b) Where the preceptor was physically present on the pharmacy premises and in the pharmacy area at the time.

6510.4 A pharmacy intern shall not change preceptors or worksites without first submitting a new preceptor form to the Board.

6510.5 A pharmacy intern shall not compound or dispense any drug by prescription except under the direct supervision of a pharmacist licensed under the Act who is physically present and guiding the action.

6510.6 A pharmacy intern shall not accept an oral prescription for a Schedule II controlled substance.

6510.7 A pharmacy intern may not perform a final review or exercise final decision-making with respect to any of the following without the prior review and approval of the licensed pharmacist: drug utilization review; clinical conflict resolution, prescriber contact concerning prescription drug order clarification or therapy modification; or dispensing process validation.

6510.8 A pharmacy intern shall be identified by badge as an intern while performing pharmacy tasks.

6510.9 A pharmacy intern shall not in any manner falsely represent or imply to the public that he or she is a pharmacist.

6510.10 A pharmacy intern shall not supervise another pharmacy intern, a pharmacy student, or a pharmacy technician.

6510.11 REPEALED

6511 DUTIES OF A PRECEPTOR

6511.1 This section shall apply only to preceptors who are supervising pharmacy interns in the performance of independent, pre-licensure professional practice in satisfaction of the internship required by § 6503 of this chapter.

6511.2 To qualify to serve as a preceptor, a pharmacist shall:

(a) Be licensed in good standing to practice pharmacy in the District of Columbia;

(b) Have been engaged in the practice of pharmacy for at least two (2) years on a full-time basis immediately prior to serving as a preceptor; and

(c) Not currently be the subject of a disciplinary sanction or investigation in any jurisdiction.

6511.3 Prior to supervising a pharmacy intern, a preceptor shall sign the "Oath of Preceptor," which states as follows:

> "I submit that I shall answer all questions concerning the training of the pharmacy intern under my supervision truthfully to the best of my knowledge and belief and that the training I provide will in accordance to the requirements set forth in 17 DCMR §§ Chapter 65 and the practice of pharmacy as required by law."

6511.4 Before allowing any person to work as a pharmacy intern, the preceptor shall verify that the person is currently registered with the Board**.**

6511.5 A preceptor shall ensure that a pharmacy intern's training consists of learning experiences that are related to the practice of pharmacy, as that term is defined in the Act in community, institutional, or clinical pharmacy practice.

6511.6 A preceptor shall be responsible for the tasks performed by a pharmacy intern. A preceptor may be disciplined for any violation of the Act or this chapter in the performance of pharmacy tasks by the intern and under the preceptor's supervision.

6511.7 A preceptor shall not supervise more than one pharmacy intern at one time while the intern is on duty and performing internship tasks without prior approval by the Board. This provision shall not apply to students who are enrolled in ACPE accredited programs while performing clerkship hours toward fulfillment of graduation requirements.

6511.8 If the preceptor has evidence of, or strongly suspects, that the pharmacy intern may have violated any law or regulation regarding the practice of pharmacy, prescription drugs or controlled substances, the preceptor shall notify the Board in

writing, within ten (10) days or immediately, if any danger to the public health or safety may exist.

6512 ADMINISTRATION OF IMMUNIZATIONS AND VACCINATIONS BY PHARMACISTS

6512.1 A pharmacist shall not administer immunizations and vaccinations unless certified by the Board of Pharmacy in accordance with this section to do so.

6512.2 An applicant for certification to administer immunizations and vaccinations shall do the following:

(a) Submit a completed application and pay the required fee;

(b) Demonstrate to the satisfaction of the Board that he or she:

(1) Is licensed in good standing under the Act to practice pharmacy;

(2) Possesses an active certification in cardiopulmonary resuscitation for health care providers; and

(3) Has successfully completed an ACPE approved course approved by the Board of Pharmacy which:

(A) Is evidence-based;

(B) Includes study material;

(C) Includes hands-on training in techniques for administering immunizations or vaccines;

(D) Requires testing with a passing score;

(E) Meets current Center for Disease Control and Prevention training guidelines; and

(F) Provides a minimum of twenty (20) hours of instruction and hands-on training in:

(i) Basic immunology and vaccine protection;

(ii) Vaccine-preventable diseases;

(iii) Vaccine storage and management;

(iv) Informed consent;

(v) Physiology and techniques for vaccine administration;

(vi) Pre and post-vaccine assessment and counseling;

(vii) Immunization record management; and

(viii) Identification, appropriate response, documentation, and reporting of adverse events.

6512.3 A pharmacist certified by the Board to administer immunizations and vaccinations shall:

(a) Maintain current certification in cardiopulmonary resuscitation for health care providers;

(b) Complete two (2) hours of continuing education each renewal period relevant to the administration of immunizations and vaccinations, as part of the continuing education credits required under subsection 6513.4 of this chapter and submit proof upon request to the Board; and

(c) Administer vaccines and immunizations in accordance with CDC guidelines.

6512.4 The location in the pharmacy where vaccinations and immunizations are administered shall:

(a) Ensure privacy;

(b) Be maintained to promote an aseptic environment;

(c) Have adequate telecommunications devices to summon aid and communicate emergency situations; and

(d) Have adequate equipment and supplies to respond to adverse events and emergency situations

6512.5 A pharmacist certified by the Board to administer immunizations and vaccinations shall only administer immunizations and vaccinations pursuant to:

(a) A written protocol signed and dated by a District of Columbia licensed physician authorizing the administration upon receipt of a written protocol; and

(b) A valid prescription; or

(c) Physician standing order

6512.6 A copy of the written protocol required in § 6512.5 shall be maintained by the administering pharmacist at the pharmacy practice site and readily available for inspection upon request of the Board of Pharmacy or submitted to the Board for review upon request.

6512.7 The written protocol shall contain, at a minimum, the following:

(a) A statement identifying the individual physician authorized to prescribe drugs and responsible for the delegation of administration of immunizations or vaccinations;

(b) A statement identifying the individual pharmacist(s) authorized to administer immunizations or vaccinations as delegated by the physician;

(c) A statement identifying the patient or groups of patients to receive the authorized immunization or vaccination; which shall be limited to:

(1) Patients who are currently under the individual physician's care or with whom the physician has provided medical treatment or care within the twelve months prior to the date of the written protocol;

(2) Patients who are currently under the practice's care or with whom a physician within the practice has provided medical treatment or care within the twelve months prior to the date of the written protocol;

(3) Residents of a health care, residential services, or assisted living facility, when the medical director of such facility is the physician making the delegation;

(4) District resident populations identified by the Director of the Department of Health as part of a public health services program, when the Director, or his or her designee, is the physician making the delegation;

(5) Inmates of the District of Columbia jail, when the medical director for the facility is the physician making the delegation; and

(6) Any person aged three (3) and older with parental consent, or valid identification if eighteen (18) or older or otherwise capable of consenting to the vaccination pursuant to Section 2 of the Consent for Vaccinations of Minors Amendment Act of 2022, effective March 10, 2023 (D.C. Law 24-12; D.C. Official Code § 7-1653.01), for any vaccination that the Advisory Committee on Immunization Practices ("ACIP") recommends according to ACIP's standard immunization schedule, or any vaccination that ACIP recommends that has been officially adopted by the Director of the Centers for Disease Control and Prevention; and

(d) A statement identifying the location(s) at which the pharmacist may administer immunizations or vaccinations which shall not include where a patient resides, except for a licensed nursing home, residential care facility, assisted living center, the District of Columbia jail, or a hospital;

(e) A statement identifying the immunizations and vaccinations and emergency anaphylactic reaction treatment that may be administered by the pharmacist;

(f) A statement identifying the activities the pharmacist shall follow in the course of administering immunizations and vaccinations, including procedures to follow in the case of reactions following administration; and

(g) A statement that describes the content of, and the appropriate mechanisms for the pharmacist to report the administration of immunizations and vaccinations to both the patient's primary physician, if applicable and sufficiently identified by the patient, and to the physician issuing the written protocol, if not the same person, within the time frames specified in the protocol; which shall include providing the physician(s) with a copy of the following records:

(1) The name, address, gender, allergies, and date of birth of the individual receiving the immunization or vaccination;

(2) The date of administration;

(3) The route and site of the immunization or vaccination;

(4) The name, dose, manufacturer's lot number, and expiration date of the vaccine;

(5) The name of the pharmacist administering the immunization or vaccination; and

(6) Any adverse events encountered.

6512.8 The pharmacist shall review the written protocol annually with the physician.

6512.9 Except as provided in § 6512.10, a pharmacist certified by the Board to administer immunizations and vaccinations shall not administer an immunization or vaccination to any individual younger than twelve (12) years old and must obtain acceptable proof of age before administration.

6512.10 A pharmacist certified by the Board to administer immunizations and vaccinations shall only administer an immunization or vaccination to an individual under the age of twelve (12) upon a referral from a physician who has an established physician-patient relationship with the patient.

6512.11 Except as provided in § 6512.12, a pharmacist certified to administer immunizations and vaccinations shall not delegate any function or duty, in part or in whole, pertaining to the administration of immunizations and vaccinations.

6512.12 A pharmacist certified to administer immunizations and vaccinations may permit a pharmacy student in a pharmacy experiential program, who has successfully completed a Board-approved certification course to administer influenza vaccinations under the pharmacist's direct supervision to an individual who is eighteen (18) years of age or older.

6512.13 Every patient receiving an immunization or vaccination by a pharmacist certified to do so, shall be provided with:

(a) A current vaccine information statement; and

(b) A copy of the administration records required in § 6512.7(g).

6512.14 The pharmacist shall obtain the patient's informed written consent prior to administering the immunization or vaccination.

6512.15 As part of the informed consent**,** the practitioner and the pharmacist shall provide written disclosure to the patient of any contractual arrangement with any other party or any financial incentive that may impact one of the party's decisions to participate in the agreement.

6512.16 The pharmacist shall maintain a copy of the patient's informed written consent on file at the pharmacy practice site where the administration was given for a period of two (2) years after the date of administration.

6512.17 The pharmacist shall maintain documentation at the pharmacy practice site where the immunization or vaccination was administered for a period of two (2) years that includes:

(a) The name, address, gender, allergies and date of birth of the individual receiving the immunization or vaccination;

(b) The date of administration

(c) The route and site of the immunization or vaccination;

(d) The name, dose, manufacturer's lot number, and expiration date of the vaccine;

(e) The name and address of the primary health care provider of the individual receiving the immunization or vaccination as identified to the pharmacist by that individual;

(f) The date on which the vaccination or immunization information was reported to the delegating physician and to the primary care physician, if applicable;

(g) The name of the pharmacist administering the immunization or vaccination;

(h) The version of the vaccination information statement provided to the patient;

(i) A copy of the signed patient informed consent form; and

(j) Any adverse events encountered.

6512.18 The records required to be maintain pursuant to this chapter shall be readily available for inspection upon request of the Board of Pharmacy or submitted to the Board for review upon request.

6512.19 A pharmacist certified under this chapter may administer the vaccinations and immunizations, and emergency anaphylactic reaction treatment deemed appropriate by the delegating physician as specifically set forth in the written protocol.

6512.20 The administering pharmacist shall report the immunizations and vaccinations administered as required under any federal or District Immunization Information System or Immunization Registry or as otherwise agreed in the written protocol.

6512.21 The administering pharmacist shall report any adverse event, which occurs in connection with or related to an administration to:

(a) The Department of Health's Pharmaceutical Control Division within forty-eight (48) hours after discovery of the occurrence; and

(b) The Director of the Department of Health as required under the District's Mandatory Adverse Event Reporting law and regulations in D.C. Official Code § 7-161 (2011 Supp.) and 17 DCMR § 4017.4.

6513 CONTINUING EDUCATION REQUIREMENTS

6513.1 Except as provided in § 6513.2, this section shall apply to applicants for the renewal, reactivation, or reinstatement of a pharmacist license.

6513.2 This section shall not apply to applicants for an initial license by examination or reciprocity, nor does it apply to applicants for the first renewal of a license.

6513.3 A continuing education credit shall be valid only if it is part of a program approved by the Board in accordance with § 6514 of this chapter.

6513.4 For the licensure period ending February 28, 2021, an applicant for renewal of a license shall:

(a) Have completed a minimum of forty (40) contact hours of continuing education credit in approved programs during the two (2) year period preceding the date the license expires, all of which may be satisfied through approved online courses, and which shall include at least:

(1) Two (2) hours in Human Immunodeficiency Virus (HIV) training;

(2) Two (2) hours in medication/dispensing errors training; and

(3) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ") meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(b) Attest to completion of the required continuing education credits on the renewal application form; and

(c) Be subject to a random audit.

6513.5 Beginning with the licensure period ending February 28, 2023, an applicant for renewal of a license shall:

(a) Have completed a minimum of forty (40) contact hours of continuing education credit in approved programs during the two (2) year period preceding the date the license expires, which shall include at least:

(1) Two (2) hours in medication/dispensing errors training;

(2) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who

identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ") meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(3) At least ten percent (10%) of the total required continuing education shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the *D.C. Register*. The Board shall disseminate the identified subjects to its licensees when determined by the Director via electronic communication and through publication on its website; and

(b) Attest to completion of the required continuing education credits on the renewal application form; and

(c) Be subject to a random audit.

6513.6 With the exception of the licensure renewal period ending February 28, 2021, not more than thirty (30) contact hours of continuing education credit may be accepted in any renewal period, or for reinstatement or reactivation of a license for approved home study or other mediated instruction continuing education courses.

6513.7 With the exception of the licensure renewal period ending February 28, 2021, a minimum of ten (10) contact hours of the required continuing education credits for renewal, reinstatement, or reactivation of a license shall be obtained by attendance at live continuing education programs.

6513.8 For the licensure period ending February 28, 2021, to qualify for a license, a person in inactive status within the meaning of § 511 of the Act (D.C. Official Code § 3-1205.11) for five (5) years or less, who submits an application to reactivate a license, shall submit proof, pursuant to § 6513.14, of having completed twenty (20) contact hours of approved continuing education credit in the year immediately preceding the date of the application, all of which may be satisfied through approved online courses, and which shall include at least:

(a) Two (2) hours in Human Immunodeficiency Virus (HIV) Training;

(b) Two (2) hours in medication/dispensing errors training; and

(c) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5).

6513.9 Beginning with the licensure period ending February 28, 2023, to qualify for a license, a person in inactive status within the meaning of § 511 of the Act (D.C. Official Code § 3-1205.11) for five (5) years or less, who submits an application to reactivate a license, shall submit proof, pursuant to § 6513.14, of having completed twenty (20) contact hours of approved continuing education credit in the year immediately preceding the date of the application, which shall include at least:

(a) Two (2) hours in medication/dispensing errors training;

(b) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(c) At least ten percent (10%) of the total required continuing education shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the *D.C. Register*. The Board shall disseminate the identified subjects to its licensees when determined by the Director via electronic communication and through publication on its website.

6513.10 For the licensure period ending February 28, 2021, to qualify for a license, a person in inactive status within the meaning of § 511 of the Act (D.C. Official Code § 3-1205.11) for more than five (5) years, who submits an application to reactivate a license shall submit proof, pursuant to § 6513.14, of having completed approved continuing education credit in the year immediately preceding the date of the application, as follows:

(a) Forty (40) contact hours of approved continuing education credit, all of which may be satisfied through approved online courses, and which shall include at least:

(1) Two (2) hours in Human Immunodeficiency Virus (HIV) training;

(2) Two (2) hours in medication/dispensing errors training; and

(3) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and

expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a).

6513.11 Beginning with the licensure period ending February 28, 2023, to qualify for a license, a person in inactive status within the meaning of § 511 of the Act (D.C. Official Code § 3-1205.11) for more than five (5) years, who submits an application to reactivate a license shall submit proof, pursuant to § 6513.14, of having completed approved continuing education credit in the year immediately preceding the date of the application as follows:

(a) Forty (40) contact hours of approved continuing education credit which shall include at least:

(1) Two (2) hours in medication/dispensing errors training;

(2) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(3) At least ten percent (10%) of the total required continuing education shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the *D.C. Register*. The Board shall disseminate the identified subjects to its licensees when determined by the Director via electronic communication and through publication on its website; and

(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a).

6513.12 For the licensure period ending February 28, 2021, to qualify for a license, an applicant for reinstatement of a license shall submit proof, pursuant to § 6513.14, of having completed approved continuing education credit in the year immediately preceding the date of the application as follows:

(a) Forty (40) contact hours of approved continuing education credit, all of which may be satisfied through approved online courses, and which shall include at least:

(1) Two (2) hours in Human Immunodeficiency Virus (HIV) Training;

(2) Two (2) hours in medication/dispensing errors training; and

(3) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a).

6513.13 Beginning with the licensure period ending February 28, 2023, to qualify for a license, an applicant for reinstatement of a license shall submit proof, pursuant to § 6513.14, of having completed approved continuing education credit in the year immediately preceding the date of the application as follows:

(a) Forty (40) contact hours of approved continuing education credit which shall include at least:
(1) Two (2) hours in medication/dispensing errors training;

(2) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(3) At least ten percent (10%) of the total required continuing education shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the *D.C. Register*. The Board shall disseminate the identified subjects to its licensees when determined by the Director via electronic communication and through publication on its website; and

(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a).

6513.14 Except as provided in § 6513.16, an applicant under this section shall prove completion of required continuing education credits by submitting with the

application the following information with respect to each program:

(a) The name and address of the sponsor of the program;

(b) The name of the program, its location, a description of the subject matter covered, and the names of the instructors;

(c) The dates on which the applicant attended the program;

(d) The hours of credit claimed; and

(e) Verification by the sponsor of completion, by signature or stamp.

6513.15 The Board shall conduct a random audit of continuing education credits at the completion of each renewal period.

6513.16 Applicants for renewal of a license shall only be required to prove completion of the required continuing education credits by submitting proof pursuant to § 6513.14 if requested to do so as part of the random audit, or if otherwise requested to do so by the Board.

6513.17 Persons selected as a part of the Board's random audit shall provide all requested documentation within no more than thirty (30) calendar days after receipt of the audit request or having been deemed served with receipt, whichever comes first.

6513.18 An applicant for renewal of a license who fails to renew the license by the date the license expires may renew the license for up to sixty (60) days after the date of expiration by completing the application, submitting the required supporting documents, and paying the required late fee. Upon renewal, the applicant shall be deemed to have possessed a valid license during the period between the expiration of the license and the renewal thereof.

6513.19 If an applicant for renewal of a license fails to renew the license and pay the late fee within sixty (60) days after the expiration of applicant's license, the license shall be considered to have lapsed on the date of expiration. The applicant shall thereafter be required to apply for reinstatement of an expired license and meet all requirements and fees for reinstatement.

6513.20 The Board may, in its discretion, grant an extension of the sixty (60) day period, up to a maximum of one (1) year, to renew after expiration if the applicant's failure to renew was for good cause. As used in this section, "good cause" includes the following:

(a) Serious and protracted illness of the applicant; and

(b) The death or serious and protracted illness of a member of the applicant's immediate family.

6513.21 An extension granted under this section shall not exempt the pharmacist from complying with the continuing education requirements for any other renewal period.

6514 APPROVED CONTINUING EDUCATION PROGRAMS

6514.1 The Board may, in its discretion, approve continuing education programs that contribute to the growth of an applicant in professional competence in the practice of pharmacy and which meet the other requirements of this section.

6514.2 The Board may approve continuing education programs that meet the requirements of § 6514.3 and provide instruction in one of the following subjects:

(a) Properties and actions of drugs and drug dosage forms;

(b) Etiology, characteristics, and therapeutics of the disease state;

(c) Pharmaceutical practice;

(d) Legal, psychological, and socio-economic aspects of health care delivery; or

(e) Principles, techniques, and theories of pharmacy management and administration.

6514.3 To qualify for approval by the Board, a continuing education program shall be a lecture, conference, seminar, course of instruction, or workshop and be prepared, offered, or administered by one of the following:

(a) Providers approved by the ACPE;

(b) The Accreditation Council for Continuing Medical Education (sponsored or co-sponsored) and designated as an American Medical Association Physician’s Recognition Award Category 1 program by the sponsoring organization;

(c) A governmental unit;

(d) A health care facility; or

(e) An institution of higher learning recognized by an accrediting body approved by the Secretary of the United States Department of Education.

6514.4 The Board may issue a list of approved continuing education programs.

6514.5 An applicant shall have the burden of verifying whether a program is approved by the Board pursuant to this section prior to attending the program.

6514.6 The Board may approve the following continuing education activities by an applicant:

(a) Serving as an instructor or speaker at a lecture, conference, seminar, workshop, course of instruction, or in-service training; and

(b) Publication of an article or book review in a professional journal or bulletin or publication of a book or chapter in a book.

6515 CONTINUING EDUCATION CREDITS

6515.1 A contact hour shall consist of at least fifty (50) minutes of instruction in an approved continuing education program and shall equal one-tenth (0.1) of a continuing education credit ("CEU").

6515.2 For approved undergraduate or graduate courses, each semester hour of credit constitutes fifteen (15) contact hours of continuing education credit, and each quarter hour constitutes ten (10) contact hours of continuing education credit.

6515.3 The Board may grant a maximum of ten (10) contact hours of continuing education credits per year to an applicant who attends in-service education programs.

6515.4 The Board may grant credit for both preparation and presentation time to an applicant who serves as an instructor or speaker at an acceptable program, subject to the following restrictions:

(a) The maximum amount of credit which may be granted for preparation time is twice the amount of the associated presentation time; and

(b) The maximum amount of credit which may be granted pursuant to this subsection is fifty percent (50%) of an applicant's continuing education requirement; and

(c) The presentation must have been completed during the period for which credit is claimed.

6515.5 The Board may grant an applicant who is an author or editor of a published book in the field of pharmacy thirty (30) contact hours of continuing education credits, if the book has been published or accepted for publication during the period for

which credit is claimed, and the applicant submits proof of this fact with the application.

6515.6 The Board may grant an applicant who is an author of a published original paper in the field of Pharmacy eight (8) contact hours of continuing education credits, subject to the same restrictions set forth for books in § 6515.5.

6515.7 The Board may grant an applicant who is the sole author of a published book review, review paper, or abstract, in the field of Pharmacy, two (2) contact hours of continuing education credits, subject to the same restrictions set forth for books in § 6515.5.

6516 COVID-19 TESTING BY PHARMACISTS

6516.1 A pharmacist licensed in good standing in the District of Columbia shall only perform COVID-19 tests as set forth in this section.

6516.2 For purposes of this section, the terms "COVID-19 test" and "COVID-19 testing" shall refer to COVID-19 diagnostic tests, COVID-19 antibody tests, and any other tests and testing mechanisms for COVID-19 that are approved by the United Stated Food and Drug Administration (FDA), or that are authorized under a FDA Emergency Use Authorization (EUA), and for which a waiver has been granted under § 2 of the Clinical Laboratory Improvement Amendments Act (42 U.S.C. § 263a) (CLIA).

6516.3 For purposes of this section, the phrase "administer COVID-19 tests" or "administer COVID-19 testing" shall mean to administer a diagnostic COVID-19 test to a patient.

6516.4 For purposes of this section, the phrase "observe and facilitate collection of self-administered COVID-19 tests" or "observe and facilitate collection of self-administered COVID-19 testing" shall mean to observe a patient self-administer a diagnostic COVID-19 test to himself or herself.

6516.5 For purposes of this section, the phrase "administer COVID-19 antibody test" or "administer COVID-19 serology test" shall mean to obtain a specimen from a patient through fingerstick, nasal swab, or other CLIA-waived point of care test for purposes of testing for COVID-19 antibodies.

6516.6 For purposes of this section, the phrase "processing a COVID-19 antibody test" shall mean to analyze a specimen through the use of a CLIA-waived testing mechanism to detect the presence of COVID-19 antibodies.

6516.7 Only a pharmacist licensed in good standing in the District of Columbia shall administer, or supervise a licensed pharmacy intern, or registered pharmacy

technician in administering, diagnostic COVID-19 testing.

6516.8 The location site where diagnostic COVID-19 testing is administered shall meet the requirements set forth in § 6516.9 or § 6516.10 of this chapter.

6516.9 A COVID-19 testing location operated by a pharmacy in a non-institutional pharmacy setting that performs diagnostic COVID-19 testing shall:

(a) Be an outdoor location in close proximity to the pharmacy building, such as a parking lot; which may include drive up, curbside, or walk up access;

(b) Not be located within six (6) feet of the entrance of the pharmacy building;

(c) Have and follow a plan for the safe operation of the testing site, and an infection control plan; and

(d) Maintain a record of all patients who have undergone COVID-19 testing at the testing location. This information shall be maintained by the pharmacy for at least one year unless otherwise directed by the Department of Health.

6516.10 A COVID-19 testing location operated by a pharmacy in an off-site location that performs diagnostic COVID-19 testing shall by approved by the Director, subject to inspection by the Department, and comply with all relevant Center for Disease Control and Prevention ("CDC") requirements and guidelines for the operation of testing locations available on the CDC website (www.cdc.gov), as they may be from time to time amended.

6516.11 All pharmacists, pharmacy interns, and pharmacy technicians involved in administering diagnostic COVID-19 testing shall comply with current CDC requirements and guidelines for personnel collecting specimens or working within six (6) feet of patients available on the CDC website (www.cdc.gov), as they may be from time to amended.

6516.12 The pharmacist-in-charge of a pharmacy where diagnostic COVID-19 testing will be administered, shall:

(a) Implement appropriate policies and procedures for the safe performance of COVID-19 testing at that location, which shall include ensuring compliance with current CDC requirements and guidelines for appropriate training, collection procedures, availability and use of PPE, and proper disposal of used PPE available on the CDC website (www.cdc.gov), as they may be from time to time amended; and

(b) Staff the pharmacy in a manner to ensure that the pharmacist(s) who is

administering or supervising the administration of diagnostic COVID-19 testing is engaged solely in administering or supervising the administration of diagnostic COVID-19 testing and is not dispensing prescriptions or counseling patients in between administering COVID-19 testing. The pharmacist performing COVID-19 testing shall only dispense prescriptions and counsel patients after all COVID-19 testing has been completed for the period during which he or she has been assigned to perform testing, after properly disposing of his or her PPE, and after thoroughly washing his or her hands.

6516.13 Only a pharmacist licensed in good standing in the District of Columbia shall observe and facilitate collection of self-administered COVID-19 testing or supervise a licensed pharmacy intern or registered pharmacy technician in observing and facilitating collection of self-administered COVID-19 testing.

6516.14 The location site where authorized pharmacy personnel observe and facilitate collection of self-administered COVID-19 testing occurs shall meet the requirements set forth in § 6516.10 or § 6516.15 of this chapter.

6516.15 Except as provided in § 6516.10 or § 6516.16, a COVID-19 testing location operated by a pharmacy in a non-institutional pharmacy setting where authorized pharmacy personnel observe and facilitate collection of self-administered COVID-19 testing shall:

(a) Be an outdoor location in close proximity to the pharmacy building, such as a parking lot; which may include drive up, curbside, or walk up access;

(b) Not be located within six (6) feet of the entrance of the pharmacy building;

(c) Have and follow a plan for the safe operation of the testing site, and an infection control plan; and

(d) Maintain a record of all patients who have undergone COVID-19 testing at the testing location. This information shall be maintained by the pharmacy for at least one year unless otherwise directed by the Department of Health.

6516.16 A COVID-19 testing location operated by a pharmacy in a non-institutional setting where authorized pharmacy personnel observe and facilitate collection of self-administered COVID-19 testing may perform the observation through a drive through window only if the pharmacy complies with the requirements set forth below:

(a) The pharmacy implements procedures for a contactless and one-way

directional observation and collection process, which shall ensure that nothing passes from the patient into the pharmacy including identification cards, payment, testing orders, or writing utensils;

(b) All pharmacy personnel shall remain greater than six (6) feet from the patient or behind a closed glass window at all times during the observation and collection; and

(c) The patient places the sealed specimen directly into an outdoor collection bin without aid or assistance from any pharmacy personnel.

6516.17 All pharmacists, pharmacy interns, and pharmacy technicians who observe and facilitate collection of self-administered COVID-19 testing shall comply with current CDC requirements and guidelines for PPE for personnel who are handling specimens but not directly involved in collection and who are not working within six (6) feet of the patient available on the CDC website (www.cdc.gov), as they may be from time to time amended.

6516.18 The pharmacist-in-charge of a pharmacy where authorized pharmacy personnel observe and facilitate collection of self-administered COVID-19 testing, shall implement appropriate policies and procedures for the safe performance of COVID-19 testing at that location, which shall include ensuring compliance with current CDC requirements and guidelines for appropriate training, collection procedures, availability and use of PPE, proper disposal of used PPE, and appropriate staffing levels available on the CDC website (www.cdc.gov), as they may be from time to time amended.

6516.19 Only a pharmacist licensed in good standing in the District of Columbia shall administer or supervise a licensed pharmacy intern, or registered pharmacy technician to administer a COVID-19 antibody or serology test.

6516.20 The location site where COVID-19 antibody or serology testing is administered which requires removal of a patient's mask, or in which the patient's sputum or other bodily fluids may potentially become aerosolized, shall meet the requirements set for in § 6516.9 or § 6516.10 of this chapter.

6516.21 The location site where COVID-19 antibody or serology testing occurs using fingerstick or other point of care testing in which there is no potential for the patient's bodily fluids to become aerosolized, shall meet the requirements set forth in § 6516.22 of this chapter.

6516.22 A COVID-19 testing location operated by a pharmacy in a non-institutional setting where authorized pharmacy personnel administer COVID-19 antibody or serology testing in which there is no potential for the patient's bodily fluids to become aerosolized shall:

(a) Ensure patient privacy;

(b) Have and follow a plan for the safe operation of the testing site, and an infection control plan; and

(c) Maintain a record of all patients who have undergone COVID-19 testing at the testing location. This information shall be maintained by the pharmacy for at least one year unless otherwise directed by the Department of Health.

6516.23 All pharmacists, pharmacy interns, and pharmacy technicians who administer COVID-19 antibody or serology testing shall comply with current CDC requirements and guidelines for PPE for personnel who are handling specimens but not directly involved in collection and who are not working within six (6) feet of the patient available on the CDC website (www.cdc.gov), as they may be from time to time amended.

6516.24 The pharmacist-in-charge of a pharmacy where authorized pharmacy personnel administer COVID-19 antibody or serology testing, shall implement appropriate policies and procedures for the safe performance of COVID-19 testing at that location, which shall include ensuring compliance with current CDC requirements and guidelines for appropriate training, collection procedures, availability and use of PPE, proper disposal of used PPE, and appropriate staffing levels available on the CDC website (www.cdc.gov) as they may be from time to time amended.

6516.25 Prior to performing COVID-19 testing, a pharmacist shall review and familiarize himself/herself with the Center for Disease Control's "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)" available on the CDC website (www.cdc.gov) as they may be from time to time amended, and ensure that the pharmacist and authorized pharmacy personnel have appropriate PPE to safely perform the testing.

6516.26 The health care practitioner who orders the COVID-19 test, who may be the same pharmacist who administers the test, shall be responsible for receiving the test results and directing a patient with a positive test result to receive care and monitoring.

6517 RESERVED

6518 REPEALED

6599 DEFINITIONS

6599.1 As used in this chapter, the following terms have the meanings ascribed:

ACPE— The Accreditation Council for Pharmacy Education.

Act- The District of Columbia Health Occupation Revision Act of 1985 ("Act"), effective March 25, 1986 (D.C. Law 6-99; D.C. Official Code § 3-1201.01 et seq.)

Administer— The direct application of a prescription drug by injection, inhalation, ingestions, or any other means to the body of a patient

Adulterated drug or device – an adulterated drug or device as defined in § 501 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 351.

Applicant – a person applying for a license to practice pharmacy under this chapter.

Board – the Board of Pharmacy, established by § 208 of the Act, D.C. Official Code § 3-1202.08 (2001).

Coded prescription – a prescription employing words and symbols chosen by the prescriber and a cooperating pharmacist for secrecy from other pharmacists.

Contact hour – a period of at least fifty (50) minutes of instruction in a continuing education program. One (1) contact hour equals one-tenth (0.1) of a continuing education credit.

Department—The District of Columbia Department of Health.

Director— The Director of the District of Columbia Department of Health.

Distribution--the actual, constructive, or attempted transfer from one person to another, other than by administering or dispensing, of a drug or medical device whether or not there is an agency relationship.

Enrolled in a pharmacy program—In order to be considered enrolled in a school of pharmacy, a person shall not be absent from school for more than two (2) consecutive semesters or three (3) consecutive quarters.

FPGEC- Foreign Pharmacy Graduate Examination Committee.

Home-Study and other Mediated Instruction - Covers all continuing education activities, including Internet courses, which do not provide for direct interaction between faculty and participants and may include audio tapes, video tapes, cable television, computer assisted instruction, journal articles, monographs, etc.

Immunization— The act of inducing antibody formation, thus leading to immunity.

MPJE- Multistate Pharmacy Jurisprudence Examination for the District of Columbia

NABP- National Association of Boards of Pharmacy

NAPLEX- North American Pharmacist Licensure Examination

Pharmacist – a person licensed to practice pharmacy under the Act.

Pharmacy intern – a person registered in the District to practice pharmacy under the direct supervision of a pharmacist and who is fulfilling internship (sometimes called externship) requirements in accordance with the chapter.

Preceptor – means a pharmacist licensed in good standing in the District, who has been approved by the Board to supervise the pre-licensure professional practice of a pharmacy intern.

Prescriber – a health professional licensed in the United States and authorized by law to prescribe the particular drug or device.

Prescription Drug – one of the following drugs:

(a) A drug which under federal law is required, prior to being dispensed or delivered, to be labeled in substance with either of the following statements:

(1) "Caution: Federal law prohibits dispensing without prescription"; or

(2) "Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.";

(b) A drug which is required by any applicable federal or District law or regulation to be dispensed on prescription only; or

(c) A drug that is restricted to use by health professional and allied practitioners for research.

Registration – a document issued by the Board authorizing a pharmacy intern to do pre-licensure professional practice in the District with a designated preceptor.

Supervised practice letter— document issued by the Board authorizing the individual to practice the same scope of duties as a pharmacy intern under the supervision of a pharmacist licensed under the Act, while his or her application for licensure in the District of Columbia is pending or as otherwise authorized by the Board.

Vaccination— Administration of any antigen in order to induce immunity; is not

synonymous with immunization since vaccination does not imply success.

Written protocol— a specific written plan for a course of medical treatment containing a written set of specific directions created by the physician for one or more patients.

6599.2 The definitions in § 4099 of chapter 40 of this title are incorporated by reference and made applicable to this chapter.